Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib For Treatment-Naive, Cytopenic Myelofibrosis

NCT07498205 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT07498205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07498205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib For Treatment-Naive, Cytopenic Myelofibrosis
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
August 8, 2031
Enrollment
268 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, myelofibrosis (mf)